Atlas Trials

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Clinical trial NCT04043195 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04043195
Sponsor
Hatim Husain
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced NSCLC
Start date
2019-08-14
Primary completion
2025-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.